Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Neogap Therapeutics AB is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners, but both are located within 1 distinct art unit. This indicates that while the company's technology is focused within a single art unit, it is subject to review by multiple individuals, providing a slightly broader perspective on examination practices within that unit.
AMY E JUEDES is the busiest examiner for the company, managing 1 pending office action. As there are 2 pending office actions in total, this examiner is responsible for 1 of them. The use of 1 distinct art unit for both actions suggests a consistent administrative environment for the company's current biotechnology prosecution. This structure allows the company to compare the feedback from 2 distinct examiners while remaining within the administrative framework of a single art unit in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | JOHANSEN, PETER N. | 17d overdue |
| 18003279 | IMMUNOTHERAPY | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18003279 | IMMUNOTHERAPY | JUEDES, AMY E | 1644 | §103DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | JOHANSEN, PETER N. | 1644 | §112 | Non-Final OA | 17d overdue | Pending | Jun 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial